Since survivors had lower levels of KP-metabolites at the latest measurement timepoint, which may be associated with a better response to PAH therapy, we compared the survival curves in PAH patients based on the latest available measurement. This evidence concerns the gene NPPA and pulmonary arterial hypertension.